BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, February 23, 2026
Home » Authors » Jim Stommen

Articles by Jim Stommen

The MDD Interview: Heart failure focus provides broad potential market for BioControl

June 27, 2013
By Jim Stommen

The MDD Interview: Putting the theories of recruitment into practice for start-up firm

June 20, 2013
By Jim Stommen

The MDD Interview: Allen: Getting to know people is key in meshing hires with companies

June 13, 2013
By Jim Stommen
Julie Allen is founder and managing partner of Allen Executive Search (Oconomowoc, Wisconsin), whose focus is on recruiting for early-stage, venture-backed and small-to-medium-sized companies in the med-tech field. Earlier in her career, she was a director at global advertising firm Foote, Cone & Belding and also held leadership posts at Walt Disney World and Disneyland Parks.
Read More

The MDD Interview: In finding the right people that 'fit,' start-ups often have very different needs

June 6, 2013
By Jim Stommen

The MDD Interview: Siston examines importance of soft-tissue balancing in TKR

May 30, 2013
By Jim Stommen

Med-tech community wary, but at the same time optimistic about the future of the sector

May 29, 2013
By Jim Stommen
The MedTech Investing Conference held each May in Minneapolis is one of the more interesting investor-focused gatherings on the calendar. It always earns accolades from attendees as representing one of the best opportunities to bring together venture capitalists, entrepreneur/innovators and corporate development types, the latter of whom are always happy to spread the message that they’re open for business. Held for the 12th year earlier this month, the conference offered quite the reminder of the range of emotions being felt these days by those involved with or interested in med-tech. During his welcoming comments, conference co-chairman Kevin Wasserstein, founder and principal...
Read More

The MDD Interview: Study seeks to quantify improved knee-replacement outcomes

May 22, 2013
By Jim Stommen

Covidien exec sees med-tech adapting to a changing world

May 20, 2013
By Jim Stommen

The MDD Interview: JDRF: success for companies developing diabetes solutions

May 16, 2013
By Jim Stommen

12th annual MedTech Investing Conference: Changing marketplace dynamics impacting investment decisions

May 16, 2013
By Jim Stommen
Previous 1 2 3 4 5 6 7 8 9 … 31 32 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing